drugset
drugset / Trial / NCT01866254

Use of Intrathecal Hydromorphone in Elective Cesarean Deliveries

NCT01866254 ↗

Phase 0 Completed 45 enrolled Grace Shih, MD Masimo Corporation · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to determine if intrathecal hydromorphone will relieve pain as well as intrathecal morphine after cesarean delivery, with fewer side effects.

Timeline

Start
2013-05
Primary completion
2017-12-04
Completion
2018-10-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydromorphone Other / unclassified 100 ug Intrathecal
Comparator Morphine Other / unclassified 200 ug Intrathecal

Indications

No indication recorded.